| Term | Count | % |
|---|---|---|
| OCULAR HYPERAEMIA | 452 | 9.72% |
| EYE IRRITATION | 399 | 8.58% |
| EYE PAIN | 268 | 5.76% |
| EYE PRURITUS | 225 | 4.84% |
| DRUG INEFFECTIVE | 197 | 4.23% |
| DEATH | 194 | 4.17% |
| VISION BLURRED | 157 | 3.37% |
| HEADACHE | 153 | 3.29% |
| EYE SWELLING | 117 | 2.52% |
| DRY EYE | 104 | 2.24% |
| INTRAOCULAR PRESSURE INCREASED | 92 | 1.98% |
| PHOTOPHOBIA | 75 | 1.61% |
| LACRIMATION INCREASED | 71 | 1.53% |
| DIZZINESS | 67 | 1.44% |
| DYSPNOEA | 66 | 1.42% |
| HYPERSENSITIVITY | 64 | 1.38% |
| OFF LABEL USE | 56 | 1.20% |
| PRURITUS | 53 | 1.14% |
| FATIGUE | 52 | 1.12% |
| COUGH | 48 | 1.03% |
| VISUAL IMPAIRMENT | 48 | 1.03% |
| PAIN | 43 | 0.92% |
| NAUSEA | 42 | 0.90% |
| RASH | 41 | 0.88% |
| URINARY TRACT INFECTION | 40 | 0.86% |
| EYE DISCHARGE | 39 | 0.84% |
| ERYTHEMA | 37 | 0.80% |
| FOREIGN BODY SENSATION IN EYES | 35 | 0.75% |
| GLAUCOMA | 35 | 0.75% |
| PRODUCT QUALITY ISSUE | 35 | 0.75% |
| PRODUCT DOSE OMISSION ISSUE | 34 | 0.73% |
| NO ADVERSE EVENT | 31 | 0.67% |
| OCULAR DISCOMFORT | 31 | 0.67% |
| DIARRHOEA | 30 | 0.64% |
| ARTHRALGIA | 29 | 0.62% |
| FALL | 28 | 0.60% |
| NASOPHARYNGITIS | 28 | 0.60% |
| DRUG HYPERSENSITIVITY | 27 | 0.58% |
| ERYTHEMA OF EYELID | 27 | 0.58% |
| CEREBROVASCULAR ACCIDENT | 26 | 0.56% |
| VISUAL ACUITY REDUCED | 26 | 0.56% |
| ALOPECIA | 25 | 0.54% |
| BLOOD PRESSURE INCREASED | 25 | 0.54% |
| DRUG DOSE OMISSION | 25 | 0.54% |
| CATARACT | 24 | 0.52% |
| EYE INFLAMMATION | 24 | 0.52% |
| DYSPHONIA | 23 | 0.49% |
| MALAISE | 23 | 0.49% |
| RHINORRHOEA | 23 | 0.49% |
| SYNCOPE | 23 | 0.49% |
| BLEPHARITIS | 21 | 0.45% |
| HYPERTENSION | 21 | 0.45% |
| INSOMNIA | 21 | 0.45% |
| OROPHARYNGEAL PAIN | 21 | 0.45% |
| ABNORMAL SENSATION IN EYE | 20 | 0.43% |
| ASTHENIA | 20 | 0.43% |
| EYELID IRRITATION | 20 | 0.43% |
| WRONG TECHNIQUE IN PRODUCT USAGE PROCESS | 20 | 0.43% |
| CONSTIPATION | 19 | 0.41% |
| COVID-19 | 19 | 0.41% |
| DRUG INTERACTION | 19 | 0.41% |
| BURNING SENSATION | 18 | 0.39% |
| DRY MOUTH | 18 | 0.39% |
| MUSCULAR WEAKNESS | 18 | 0.39% |
| MYOCARDIAL INFARCTION | 18 | 0.39% |
| SKIN DISCOLOURATION | 18 | 0.39% |
| SKIN EXFOLIATION | 18 | 0.39% |
| EYELID OEDEMA | 17 | 0.37% |
| EYELIDS PRURITUS | 17 | 0.37% |
| TREATMENT FAILURE | 17 | 0.37% |
| ARRHYTHMIA | 16 | 0.34% |
| BLINDNESS | 16 | 0.34% |
| CHEST DISCOMFORT | 16 | 0.34% |
| PARAESTHESIA | 16 | 0.34% |
| SWELLING FACE | 16 | 0.34% |
| ABDOMINAL DISCOMFORT | 15 | 0.32% |
| BACK PAIN | 15 | 0.32% |
| DYSGEUSIA | 15 | 0.32% |
| HALLUCINATION | 15 | 0.32% |
| OVERDOSE | 15 | 0.32% |
| PAIN IN EXTREMITY | 15 | 0.32% |
| PALPITATIONS | 15 | 0.32% |
| PEMPHIGOID | 15 | 0.32% |
| PNEUMONIA | 15 | 0.32% |
| PRODUCT USE ISSUE | 15 | 0.32% |
| SOMNOLENCE | 15 | 0.32% |
| SWELLING OF EYELID | 15 | 0.32% |
| EYE HAEMORRHAGE | 14 | 0.30% |
| MUSCLE SPASMS | 14 | 0.30% |
| PERIPHERAL SWELLING | 14 | 0.30% |
| THROAT IRRITATION | 14 | 0.30% |
| URTICARIA | 14 | 0.30% |
| WEIGHT DECREASED | 14 | 0.30% |
| ABDOMINAL PAIN UPPER | 13 | 0.28% |
| ANAEMIA | 13 | 0.28% |
| ATRIAL FIBRILLATION | 13 | 0.28% |
| BALANCE DISORDER | 13 | 0.28% |
| CONJUNCTIVAL HYPERAEMIA | 13 | 0.28% |
| DRY SKIN | 13 | 0.28% |
| DYSPHAGIA | 13 | 0.28% |
| Total | 4652 |